Lehtimaki Mari, Ortega-Rodriguez Uriel, Centola Garrick, Rao V Ashutosh
Laboratory of Applied Biochemistry, Division of Biotechnology Research and Review III, Office of Biotechnology Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug Administrations, Silver Spring, Maryland 20993, United States.
Mol Pharm. 2025 May 5;22(5):2623-2638. doi: 10.1021/acs.molpharmaceut.5c00034. Epub 2025 Apr 9.
Polysorbates are common surfactants in monoclonal antibody (mAb) drug products. While polysorbates assist in stabilizing and refolding proteins, oxidative stress conditions can reduce protein stability wherein polysorbate binds to the oxidized and unfolded protein. We investigated the effects of polysorbates on the higher-order structural stability of mAbs under oxidative conditions that may occur during manufacturing, storage, and use. Secondary and tertiary structures of trastuzumab and rituximab products were investigated under two oxidative conditions: metal-catalyzed oxidation (MCO; CuSO and ascorbic acid) and 2,2'-azobis (2-aminidinopropane) dihydrochloride (AAPH) using either polysorbate-containing formulations or after polysorbate depletion. Higher-order structures were predicted from the collected circular dichroism spectra with an algorithm optimized for β-sheet structural predictions. Secondary structure analyses using circular dichroism at increasing temperatures demonstrated that MCO and AAPH triggered differing β-sheet structure degradation patterns. Rituximab products were more sensitive to MCO compared with trastuzumab products as shown by left-twisted antiparallel β-sheet structure loss and increase in unstructured elements at lower temperatures. AAPH-exposed drugs tended to have distinct unfolding states compared with the MCO-treated drugs as shown by the increase in parallel β-sheet structures for AAPH and decreased parallel β-sheet structures with MCO. Polysorbate depletion transiently improved the stability of MCO-treated material as shown by delayed circular dichroism (CD) signal degradation at 202 nm and improved peak area of the antibody monomer by nonreducing capillary electrophoresis sodium dodecyl sulfate (nrCE-SDS) and peak intensity of intact antibody in matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) analysis. The improved stability of detergent-depleted material is traced to improved stability in the predicted left-twisted β-sheet structural elements. Our data further highlights the need for formulation studies that consider the impact of polysorbate binding and/or degradation for specific drug products under stress conditions such as metal-catalyzed oxidation.
聚山梨酯是单克隆抗体(mAb)药物产品中常见的表面活性剂。虽然聚山梨酯有助于蛋白质的稳定和重折叠,但氧化应激条件会降低蛋白质稳定性,其中聚山梨酯会与氧化和未折叠的蛋白质结合。我们研究了聚山梨酯在制造、储存和使用过程中可能出现的氧化条件下对mAb高阶结构稳定性的影响。在两种氧化条件下研究了曲妥珠单抗和利妥昔单抗产品的二级和三级结构:金属催化氧化(MCO;硫酸铜和抗坏血酸)和2,2'-偶氮二(2-脒基丙烷)二盐酸盐(AAPH),使用含聚山梨酯的制剂或聚山梨酯耗尽后。利用针对β-折叠结构预测优化的算法,从收集的圆二色光谱预测高阶结构。在升高温度下使用圆二色性进行的二级结构分析表明,MCO和AAPH引发了不同的β-折叠结构降解模式。与曲妥珠单抗产品相比,利妥昔单抗产品对MCO更敏感,表现为左旋反平行β-折叠结构丧失以及在较低温度下无结构元件增加。与MCO处理的药物相比,AAPH处理的药物倾向于具有不同的解折叠状态,表现为AAPH的平行β-折叠结构增加而MCO的平行β-折叠结构减少。聚山梨酯耗尽暂时提高了MCO处理材料的稳定性,表现为在202 nm处圆二色性(CD)信号降解延迟,通过非还原毛细管电泳十二烷基硫酸钠(nrCE-SDS)提高了抗体单体的峰面积,以及在基质辅助激光解吸电离飞行时间(MALDI-TOF)分析中完整抗体的峰强度。洗涤剂耗尽材料稳定性的提高归因于预测的左旋β-折叠结构元件稳定性的提高。我们的数据进一步强调了进行制剂研究的必要性,该研究应考虑在金属催化氧化等应激条件下聚山梨酯结合和/或降解对特定药物产品的影响。